In conclusion, this review has discussed just some of the abundant data showing the clinical benefits of trastuzumab for treating HER2-positive breast cancer, including prolonging overall survival and progression-free survival, and achieving greater clinical responses. This evidence concerns the gene ERBB2 and breast carcinoma.